Apex Biotechnology (TPE:1733) Shares Outstanding (EOP): 100 Mil (As of Dec. 2025)


TPE:1733 Apex Biotechnology Corp TPE:1733
81 GF Score
Price NT$29.90
GF Value NT$30.08
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Apex Biotechnology Shares Outstanding (EOP)?

Apex Biotechnology TPE:1733 -0.17% 81 Shares Outstanding (EOP) is 100 Mil as of Dec. 2025. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Apex Biotechnology's shares outstanding for the quarter that ended in Dec. 2025 was 100 Mil.

Apex Biotechnology's quarterly shares outstanding stayed the same from Sep. 2025 (100 Mil) to Dec. 2025 (100 Mil).

Apex Biotechnology's annual shares outstanding stayed the same from Dec. 2024 (100 Mil) to Dec. 2025 (100 Mil).


Apex Biotechnology  (TPE:1733) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Apex Biotechnology Shares Outstanding (EOP) Related Terms


Apex Biotechnology Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Apex Biotechnology's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apex Biotechnology Shares Outstanding (EOP) Chart

Apex Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 99.95 99.95 99.95 99.95 99.95

Apex Biotechnology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.95 99.95 99.95 99.95 99.95

TPE:1733 vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Apex Biotechnology's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apex Biotechnology Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Apex Biotechnology's Shares Outstanding (EOP) falls into.


TPE:1733
81GF Score
Apex Biotechnology Corp TPE:1733
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apex Biotechnology Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 100 Mil mean?
Apex Biotechnology (TPE:1733) has a Shares Outstanding (EOP) of 100 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Apex Biotechnology and its competitors.
Is Apex Biotechnology's Shares Outstanding (EOP) too high?
Apex Biotechnology's current Shares Outstanding (EOP) is 100 Mil. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Shares Outstanding (EOP) compare to VRTX and REGN?
Apex Biotechnology's Shares Outstanding (EOP) of 100 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current Shares Outstanding (EOP) is 100 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current Shares Outstanding (EOP) is 100 Mil. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Shares Outstanding (EOP) is 100 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apex Biotechnology (TPE:1733) Overvalued in 2026?

Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued. The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08. GuruFocus considers Apex Biotechnology to be Fairly Valued.

Key valuation signals for TPE:1733:

  • Shares Outstanding (EOP): 100 Mil
  • GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Apex Biotechnology Business Description

Address Li-Hsin 5th Road, No. 7, Hsinchu Science Park, Hsinchu, TWN, 30078
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score

Get the complete analysis for TPE:1733

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$29.90
Price
NT$30.08
GF Value